Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Medical Devices

Myomo, Inc. is a United States-based medical device company specializing in myoelectric orthotics for people with neurological disorders. The Company’s products help to restore function in individuals with neuromuscular conditions, such as brachial plexus injury, spinal cord injury, multiple sclerosis and stroke. Its MyoPro myoelectric limb orthosis is a powered brace that supports a weakened and deformed arm for functional use. The MyoPro is an elbow/wrist/Hand orthosis, which supports the arm and helps to bend and straighten the arm at the elbow. The brace provides assistive function for joint motion that enables a user to self-initiate and control movements of a partially paralyzed arm using their own muscle signals. When the user tries to bend their arm, sensors in the brace detect the weak muscle signal, which activates the motor to amplify their weak muscle signal to help bend and move their arm. The brace uses non-invasive skin sensors.
Website: myomo.com



Growth: Good revenue growth rate 33.3%, there is slowdown compared to average historical growth rates 69.4%. The revenue growth dynamics is moderately stable

Profitability: LTM EBITDA margin is negative, -68.8%. On average the margin is improving steadily. Gross margin is high, +65.6%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 100% of quarters (showing a gain of +$0.06 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -15.9% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 750.7% higher than minimum and 75.5% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 1.2x by EV / Sales multiple , the company can be 17.0% undervalued

Insiders: For the last 3 months insiders bought company shares on $0.2 mln (0.680% of cap.)

Key Financials (Download financials)

Ticker: MYO
Share price, USD:  (+0.3%)3.43
year average price 2.11  


year start price 0.59 2023-04-29

min close price 0.44 2023-05-22

max close price 5.35 2023-12-28

current price 3.43 2024-04-27
Common stocks: 7 349 122

Dividend Yield:  0.0%
Last revenue growth (y/y):  33.3%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  69.4%
Historical growth of EBITDA:  0.0%
EV / Sales: 1.0x
Margin (EBITDA LTM / Revenue): -68.8%
Fundamental value created in LTM:
Market Cap ($m): 25
Net Debt ($m): -9
EV (Enterprise Value): 16
Price to Book: 2.8x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-03-10Seeking Alpha

Myomo, Inc.: In Motion To Accelerating Revenue Growth

2024-03-07Zacks Investment Research

Myomo, Inc. (MYO) Reports Q4 Loss, Tops Revenue Estimates

2023-12-20Zacks Investment Research

What Makes Myomo, Inc. (MYO) a Good Fit for 'Trend Investing'

2023-12-01Seeking Alpha

Myomo: Market Severely Undervaluing Opportunity

2023-11-07Seeking Alpha

Myomo, Inc. (MYO) Q3 2023 Earnings Call Transcript

2023-08-28InvestorPlace

Why Is Myomo (MYO) Stock Down 13% Today?

2023-08-09Zacks Investment Research

Myomo, Inc. (MYO) Reports Q2 Loss, Tops Revenue Estimates

2023-08-09Seeking Alpha

Myomo, Inc. (MYO) Q2 2023 Earnings Call Transcript

2023-07-05Zacks Investment Research

Myomo's (MYO) MyoPro Seeks CMS Classification for Medicare Cover

2023-05-22Zacks Investment Research

Here's Why Myomo, Inc. (MYO) Is a Great 'Buy the Bottom' Stock Now
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol MYO MYO MYO MYO MYO MYO
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-03-08 2023-11-07 2023-08-09 2023-05-10 2023-03-13 2022-11-10
acceptedDate 2024-03-07 21:38:51 2023-11-07 17:29:50 2023-08-09 16:18:01 2023-05-10 16:24:01 2023-03-13 15:49:17 2022-11-10 16:28:57
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
revenue 5M 5M 6M 3M 4M 4M
costOfRevenue 2M 2M 2M 1M 1M 1M
grossProfit 3M 3M 4M 2M 3M 3M
grossProfitRatio 0.653 0.687 0.718 0.670 0.650 0.665
researchAndDevelopmentExpenses 878 006 717 256 564 235 476 991 499 674 690 407
generalAndAdministrativeExpenses 4M 4M 0 0 0 0
sellingAndMarketingExpenses 855 700 822 500 0 0 0 0
sellingGeneralAndAdministrativeExpenses 5M 5M 5M 5M 4M 5M
otherExpenses 5313.000 -467.000 -5631.000 -31.000 14 540 0
operatingExpenses 6M 6M 5M 5M 5M 5M
costAndExpenses 7M 7M 7M 6M 6M 7M
interestIncome 113 533 112 300 103 439 86 314 40 748 0
interestExpense 0 0 0 -51 879 40 748 4345.000
depreciationAndAmortization 80 212 127 222 159 786 167 663 145 274 156 722
ebitda -2M -2M -943 220 -3M -2M -3M
ebitdaratio -0.495 -0.399 -0.158 -0.726 -0.552 -0.671
operatingIncome -2M -2M -1M -3M -2M -3M
operatingIncomeRatio -0.512 -0.399 -0.185 -0.775 -0.552 -0.710
totalOtherIncomeExpensesNet 43 874 -70 591 -18 145 69 081 38 636 12 307
incomeBeforeTax -2M -2M -1M -3M -2M -3M
incomeBeforeTaxRatio -0.502 -0.390 -0.171 -0.755 -0.542 -0.707
incomeTaxExpense 70 798 46 355 -3562.000 42 411 -23 265 23 382
netIncome -2M -2M -1M -3M -2M -3M
netIncomeRatio -0.517 -0.399 -0.170 -0.767 -0.536 -0.713
eps -0.070 -0.058 -0.036 -0.110 -0.290 -0.400
epsdiluted -0.070 -0.058 -0.036 -0.110 -0.290 -0.400
weightedAverageShsOut 35M 35M 28M 24M 7M 7M
weightedAverageShsOutDil 35M 35M 28M 24M 7M 7M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol MYO MYO MYO MYO MYO MYO
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-03-08 2023-11-07 2023-08-09 2023-05-10 2023-03-13 2022-11-10
acceptedDate 2024-03-07 21:38:51 2023-11-07 17:29:50 2023-08-09 16:18:01 2023-05-10 16:24:01 2023-03-13 15:49:17 2022-11-10 16:28:57
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 7M 7M 6M 9M 5M 7M
shortTermInvestments 2M 4M 3M 0 0 0
cashAndShortTermInvestments 9M 11M 9M 9M 5M 7M
netReceivables 2M 3M 2M 2M 2M 2M
inventory 2M 1M 1M 2M 1M 1M
otherCurrentAssets 598 850 920 076 694 641 535 558 573 462 553 696
totalCurrentAssets 14M 16M 13M 13M 9M 11M
propertyPlantEquipmentNet 839 348 887 894 452 837 597 651 703 026 844 915
goodwill 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0
longTermInvestments 0 32 648 102 773 115 287 132 489 149 140
taxAssets 0 0 0 0 0 0
otherNonCurrentAssets 91 237 91 237 111 034 111 034 111 034 111 034
totalNonCurrentAssets 930 585 1M 666 644 823 972 946 549 1M
otherAssets 0 0 0 0 0 0
totalAssets 15M 17M 13M 14M 10M 12M
accountPayables 1M 5M 766 583 906 805 3M 878 600
shortTermDebt 486 143 456 064 181 783 275 028 353 701 441 386
taxPayables 96 461 65 576 177 187 182 768 48 220 0
deferredRevenue 8510.000 30 685 844 519 933 336 20 653 738 153
otherCurrentLiabilities 4M 65 576 3M 2M 48 220 2M
totalCurrentLiabilities 5M 6M 4M 4M 4M 4M
longTermDebt 115 160 253 210 139 657 169 770 200 207 220 901
deferredRevenueNonCurrent 0 0 126.000 312.000 498.000 685.000
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0
otherNonCurrentLiabilities -1.000 -1.000 0 0 0 -2M
totalNonCurrentLiabilities 115 159 253 209 139 783 170 082 200 705 221 586
otherLiabilities 1.000 0 0 0 0 0
capitalLeaseObligations 115 160 709 274 321 440 444 798 553 908 662 287
totalLiabilities 6M 6M 4M 4M 4M 4M
preferredStock 0 0 0 0 0 0
commonStock 2715.000 2652.000 2110.000 2092.000 775.000 706.000
retainedEarnings -97M -94M -92M -91M -89M -87M
accumulatedOtherComprehensiveIncomeLoss 83 669 -8554.000 39 292 109 015 43 227 -11 466
othertotalStockholdersEquity 106M 105M 101M 101M 95M 94M
totalStockholdersEquity 9M 11M 9M 10M 6M 8M
totalEquity 9M 11M 9M 10M 6M 8M
totalLiabilitiesAndStockholdersEquity 15M 17M 13M 14M 10M 12M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 15M 17M 13M 14M 10M 12M
totalInvestments 2M 4M 3M 115 287 132 489 149 140
totalDebt 601 303 709 274 321 440 444 798 553 908 662 287
netDebt -6M -6M -6M -9M -5M -7M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol MYO MYO MYO MYO MYO MYO
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-03-08 2023-11-07 2023-08-09 2023-05-10 2023-03-13 2022-11-10
acceptedDate 2024-03-07 21:38:51 2023-11-07 17:29:50 2023-08-09 16:18:01 2023-05-10 16:24:01 2023-03-13 15:49:17 2022-11-10 16:28:57
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
netIncome -2M -2M -1M -3M -2M -3M
depreciationAndAmortization 80 212 127 222 159 786 150 461 145 274 140 070
deferredIncomeTax -1M 69 750 -3562.000 0 0 0
stockBasedCompensation 334 089 330 425 280 061 171 027 273 368 305 633
changeInWorkingCapital -295 053 -174 703 336 064 426 903 -744 048 -461 613
accountsReceivables 129 997 -861 473 -104 656 340 533 -315 314 -239 274
inventory -294 681 -159 007 226 055 -157 148 145 320 -256 191
accountsPayables -351 845 1M 501 714 386 880 0 0
otherWorkingCapital 221 476 -407 607 -287 049 -143 362 -574 054 33 852
otherNonCashItems 996 154 -38 484 -43 722 79 214 28 635 46 902
netCashProvidedByOperatingActivities -2M -2M -285 523 -2M -2M -3M
investmentsInPropertyPlantAndEquipment -31 665 -54 093 -14 973 -45 085 -3385.000 -5736.000
acquisitionsNet -2M 1M 3M 0 199 000 0
purchasesOfInvestments -673 883 -2M -3M 0 0 0
salesMaturitiesOfInvestments 3M 750 000 250 000 0 0 0
otherInvestingActivites 2M -1M -3M 0 -199 000 0
netCashUsedForInvestingActivites 2M -1M -3M -45 085 -3385.000 -5736.000
debtRepayment 0 0 0 0 0 0
commonStockIssued 0 6M 0 4M 376 858 0
commonStockRepurchased 31.000 -4M -8147.000 0 0 0
dividendsPaid 0 0 0 0 0 0
otherFinancingActivites 31.000 2M 0 2M 0 0
netCashUsedProvidedByFinancingActivities 31.000 4M -8147.000 6M 376 858 0
effectOfForexChangesOnCash 20 821 -13 921 3M 7311.000 16 695 -11 434
netChangeInCash -40 441 905 464 -3M 4M -2M -3M
cashAtEndOfPeriod 7M 7M 6M 9M 5M 7M
cashAtBeginningOfPeriod 7M 6M 9M 5M 7M 10M
operatingCashFlow -2M -2M -285 523 -2M -2M -3M
capitalExpenditure -31 665 -54 093 -14 973 -45 085 -3385.000 -5736.000
freeCashFlow -2M -2M -300 496 -2M -2M -3M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

2023 q4
2024-03-07 ET (fiscal 2023 q4)
2023 q3
2023-11-07 ET (fiscal 2023 q3)
2023 q2
2023-08-09 ET (fiscal 2023 q2)
2023 q1
2023-05-11 ET (fiscal 2023 q1)
2022 q4
2023-03-13 ET (fiscal 2022 q4)
2022 q3
2022-11-10 ET (fiscal 2022 q3)
2022 q2
2022-08-06 ET (fiscal 2022 q2)
2022 q1
2022-05-11 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-03-07 21:05 ET
Myomo Reports Fourth Quarter and Full Year 2023 Financial Results
2024-03-01 13:00 ET
CMS Posts Final Medicare DMEPOS Fee Schedule Rate for the MyoPro®
2024-02-29 21:05 ET
Myomo to Report Fourth Quarter Financial Results on March 7, 2024
2024-01-17 13:05 ET
Myomo Announces $6 Million Registered Direct Offering of Common Stock Priced At-the-Market
2024-01-17 13:00 ET
Myomo Reports Preliminary Fourth Quarter Revenue and Backlog
2023-11-07 21:05 ET
Myomo Reports Third Quarter 2023 Financial Results Featuring Record Product Revenue and Authorizations
2023-11-06 13:30 ET
CMS Posts Proposed Medicare DMEPOS Fee Schedule Rate for the MyoPro® for Review at the Upcoming HCPCS Public Meeting
2023-11-02 14:08 ET
Myomo Announces that CMS has Classified the MyoPro Orthosis Under the Brace Benefit Category
2023-10-31 20:05 ET
Myomo to Report Third Quarter Financial Results on November 7, 2023
2023-08-29 20:05 ET
Myomo Announces Closing of $4.4 Million Public Offering
2023-08-25 11:00 ET
Myomo Announces Pricing of $4.4 Million Public Offering
2023-08-24 20:15 ET
Myomo, Inc. Announces Proposed Public Offering
2023-08-24 20:05 ET
 Myomo Receives Medicare Part B Reimbursement for First MyoPro® Claims
2023-08-21 20:05 ET
Myomo Announces Two German Social Court Rulings Ordering MyoPro® Reimbursement
2023-08-09 20:05 ET
Myomo Reports Second Quarter 2023 Financial Results Featuring Year Over Year Growth in Revenue and Operating Metrics
2023-08-02 20:05 ET
Myomo to Report Second Quarter Financial Results on August 9, 2023
2023-07-03 12:30 ET
Centers for Medicare and Medicaid Services Accepts Myomo’s Application to Classify the MyoPro® as a Brace
2023-06-14 20:05 ET
Myomo To Participate in the Maxim Group Virtual Healthcare Conference Hosted by M-Vest
2023-05-10 20:05 ET
Myomo Reports First Quarter 2023 Financial Results Featuring 20% Year Over Year Increase in Product Revenue
2023-05-03 20:05 ET
Myomo to Report First Quarter Financial Results on May 10, 2023
2023-04-10 12:30 ET
Myomo Receives Technology License Fee Payment from China Joint Venture Company
2023-03-15 12:30 ET
Myomo Makes NYSE American Section 610(b) Public Announcement
2023-03-13 12:30 ET
Myomo Reports Fourth Quarter and Full Year 2022 Financial Results
2023-03-06 21:05 ET
Myomo to Report Fourth Quarter Financial Results on March 13, 2023
2023-03-06 21:05 ET
Myomo To Participate in the 35th Annual Roth Conference
2023-02-06 21:05 ET
MyoPro Approved in Australia by National Disability Insurance Scheme
2023-01-30 21:05 ET
Myomo Appoints Yitzchak Jacobovitz to its Board of Directors
2023-01-17 21:05 ET
Myomo Announces Closing of $6.5 Million Upsized Public Offering
2023-01-12 13:30 ET
Myomo Announces Pricing of $6.5 Million Upsized Public Offering
2023-01-10 21:17 ET
Myomo Announces Initiative to Reduce Cash Burn
2022-12-07 22:00 ET
Myomo Provides Update on Progress to Obtain Medicare Part B Reimbursement for MyoPro
2022-12-05 13:30 ET
Ruling by German Social Court Supports MyoPro Reimbursement by Nation’s Statutory Health Insurance System
2022-11-10 21:05 ET
Myomo Reports Third Quarter 2022 Financial Results Featuring Strong Authorizations and Orders and Record Backlog
2022-11-03 20:05 ET
Myomo to Report Third Quarter Financial Results on November 10, 2022
2022-10-05 20:30 ET
Myomo To Present at the MicroCap Rodeo Presents The Windy City Roundup 2022
2022-09-07 12:30 ET
Myomo to Present at the H.C. Wainwright 24th Annual Global Investment Conference
2022-08-30 12:30 ET
Myomo Receives Order from the Louis Stokes Cleveland VA Medical Center to Support MyoPro Clinical Trial
2022-08-03 20:05 ET
Myomo Reports Second Quarter 2022 Financial Results and Record Number of Patient Pipeline Additions
2022-07-27 20:15 ET
Myomo to Report Second Quarter Financial Results on August 3, 2022
2022-07-07 20:05 ET
Myomo Announces Second Quarter Preliminary Revenue and Record Pipeline Additions
2022-06-09 20:05 ET
Myomo To Present at the Sidoti Summer Small Cap Virtual Investor Conference
2022-05-11 20:05 ET
Myomo Reports First Quarter 2022 Financial Results
2022-05-04 20:15 ET
Myomo to Report First Quarter Financial Results on May 11, 2022
2022-04-04 20:15 ET
Myomo Reports Progress with China Joint Venture, Receives Partial Payment of Technology License Fee
2022-03-09 21:15 ET
Myomo To Participate in Two March Investor Conferences
2022-03-09 21:05 ET
Myomo Reports Fourth Quarter and Full Year 2021 Financial Results
2022-03-02 21:15 ET
Myomo to Report Fourth Quarter and Full Year 2021 Financial Results on March 9, 2022
2022-02-17 21:15 ET
Myomo Strengthens Intellectual Property Portfolio With Receipt of Key Patent in Japan
2022-02-14 13:30 ET
Independent Research with Myomo’s MyoPro® Shows Clinically Significant Gains in Motor Function in Individuals with Chronic Moderate-to-Severe Arm Weakness
2022-01-13 21:30 ET
Myomo to Present at the Sidoti Winter Small Cap Conference
2022-01-10 13:30 ET
Myomo Provides Update on MyoPro® Insurance Reimbursement
2022-01-06 21:05 ET
Myomo Announces MyoPro® 2+
2022-01-05 21:05 ET
Myomo Amends China Joint Venture Agreement, Executes Technology and Trademark License Agreement
2021-11-10 21:05 ET
Myomo Third Quarter 2021 Financial Results Feature Record Revenue
2021-11-03 20:05 ET
Myomo to Report Third Quarter 2021 Financial Results on November 10, 2021
2021-10-15 13:15 ET
Myomo, Inc. Announces Agreements for Exercise of 2020 Investor Warrants
2021-09-28 20:30 ET
Myomo, Inc. to Present at Fall Harvest - Best Ideas from the Buy-Side on October 5th
2021-09-07 20:30 ET
Myomo, Inc. Announces Granting of Patents in China and Hong Kong
2021-09-02 20:30 ET
Myomo, Inc. Announces Participation in Three September Investment Conferences
2021-08-09 20:05 ET
Myomo Second Quarter 2021 Financial Results Feature Significant Increases in Revenue and Gross Margin, Record Insurance Authorizations and Orders
2021-08-02 20:05 ET
Myomo to Report Second Quarter 2021 Financial Results on August 9, 2021
2021-07-27 12:30 ET
Myomo Receives Accreditation from HQAA
2021-07-23 20:05 ET
Myomo, Inc. Announces Participation in A.G.P.’s Virtual MedTech Summer Conference on July 29, 2021
2021-06-28 12:30 ET
Myomo, Inc. Stock Added to Russell Microcap® Index
2021-06-16 20:05 ET
Myomo to Present at Sidoti Virtual Investor Conference on June 23, 2021
2021-06-14 20:05 ET
Myomo Shareholders Elect Dr. Milton Morris as Director
2021-06-08 12:05 ET
Myomo Provides Update on CMS Discussions
2021-05-27 20:05 ET
Myomo to Present at the Summer Solstice - Best Ideas From the Buy Side Conference
2021-05-05 20:05 ET
Myomo Reports First Quarter 2021 Financial Results
2021-04-27 20:05 ET
Myomo to Report First Quarter 2021 Financial Results on May 5, 2021
2021-04-01 12:05 ET
Myomo Participates in Ground-breaking Brain-computer Interface Trial
2021-03-10 21:05 ET
Myomo Reports Fourth Quarter and Full Year 2020 Financial Results
2021-03-04 21:20 ET
Myomo to Participate in Three Investment Conferences During the Month of March
2021-03-04 21:15 ET
Myomo to Report Fourth Quarter and Full Year 2020 Financial Results on March 10, 2021
2021-02-16 13:30 ET
Germany's Largest Statutory Health Insurance Company Approves MyoPro
2021-02-12 21:05 ET
Myomo to Present at the Winter Wonderland – Best Ideas from the Buy-side Conference
2021-01-26 11:30 ET
Myomo® Forms Joint Venture to Manufacture and Sell the Company’s Products in China
2021-01-11 11:00 ET
Myomo Reports Preliminary Fourth Quarter and Full Year 2020 Results
2021-01-05 21:05 ET
Myomo to Present H.C. Wainwright Virtual BioConnect 2021 Conference
2020-11-18 14:03 ET
Myomo to Present at Sidoti & Company Virtual Microcap Conference
2020-11-16 13:30 ET
Myomo Introduces MyoGames™
2020-11-10 21:05 ET
Myomo Third Quarter Financial Results Feature Record Revenue of $1.9 Million, up 218% Over the Prior Year
2020-11-03 13:30 ET
Myomo to Report Third Quarter Financial Results on November 10, 2020
2020-11-02 13:30 ET
Myomo Appoints Dr. Harry Kovelman as Chief Medical Officer
2020-10-07 20:30 ET
Myomo to Present at the MicroCap Rodeo Best Ideas Bowl on October 13, 2020
2020-09-15 20:05 ET
Myomo Certified as Medicare Provider
2020-09-10 12:30 ET
Myomo® to Present at the H.C. Wainwright Virtual 22nd Annual Global Investment Conference
2020-08-26 20:05 ET
Myomo, Inc. to Present at The LD 500 Virtual Conference
2020-08-26 10:00 ET
Myomo® Extends and Strengthens its Global MyoPro™ Patent Portfolio
2020-08-20 10:00 ET
Myomo® Receives First Australian Insurance Authorization for MyoPro™
2020-08-10 20:05 ET
Myomo Reports 2020 Second Quarter Financial Results
2020-08-03 20:05 ET
Myomo to Report Second Quarter Financial Results on August 10, 2020
2020-07-09 10:00 ET
Myomo® Launches MyoCare™
2020-07-06 10:00 ET
Research Finds MyoPro® Delivers Meaningful Improvements in Motor Function for Brain Injury Patient
2020-06-22 10:00 ET
Myomo Resumes Fitting MyoPro Patients and Deliveries as States Begin to Re-Open after COVID-19 Shutdowns
2020-06-15 12:00 ET
Myomo® Uses Telehealth Techniques to Conduct Safe Patient Screenings
2020-05-14 20:05 ET
Myomo Reports 2020 First Quarter Financial Results
2020-05-12 20:05 ET
Myomo to Report First Quarter Financial Results on May 14, 2020
2020-04-08 12:30 ET
Myomo Reports Accelerating Growth in MyoPro Pipeline and Record Backlog in the First Quarter of 2020, Provides Update on the Business Impact of COVID-19
2020-03-18 12:30 ET
Myomo, Inc., to Present at the New York City based Investor Summit on March 25th-26th
2020-03-12 20:05 ET
Myomo Reports 2019 Fourth Quarter and Full Year Financial Results Featuring Record Revenue and Gross Margins
2020-03-05 21:05 ET
Myomo to Report Fourth Quarter and Full Year 2019 Results on March 12, 2020
2020-02-19 21:05 ET
Myomo Announces Closing of Public Offering
2020-02-19 13:00 ET
Myomo® Signs Nationwide Payer Network Agreement with HOMELINK
2020-02-11 13:59 ET
Myomo Announces Pricing of Public Offering
2020-02-06 21:05 ET
Myomo Reports Preliminary Fourth Quarter and Full Year 2019 Results
2020-02-05 17:23 ET
Myomo Not Aware of Any Developments to Account for Stock Volatility
2020-02-03 21:05 ET
MyoPro Approved for Reimbursement by German Statutory Health Insurance
2020-01-30 19:30 ET
Myomo Announces One-for-Thirty Reverse Stock Split of its Common Stock
2019-11-12 21:05 ET
Myomo Reports Third Quarter 2019 Results
2019-11-05 21:05 ET
Myomo to Report Third Quarter 2019 Results on November 12, 2019

SEC forms

Show financial reports only

SEC form 10
2024-03-08 00:00 ET
Myomo reported for 2023 q4
SEC form 10
2024-03-07 21:38 ET
Myomo reported for 2023 q4
SEC form 8
2024-03-07 16:10 ET
Myomo published news for 2023 q4
SEC form 8
2024-03-07 16:10 ET
Myomo reported for 2023 q4
SEC form 10
2023-11-07 17:29 ET
Myomo reported for 2023 q3
SEC form 8
2023-11-07 16:15 ET
Myomo reported for 2023 q3
SEC form 10
2023-11-07 00:00 ET
Myomo reported for 2023 q3
SEC form 10
2023-08-09 16:18 ET
Myomo reported for 2023 q2
SEC form 6
2023-08-09 16:11 ET
Myomo reported for 2023 q2
SEC form 10
2023-08-09 00:00 ET
Myomo reported for 2023 q2
SEC form 8
2023-08-09 00:00 ET
Myomo reported for 2023 q2
SEC form 6
2023-06-09 08:30 ET
Myomo published news for 2023 q1
SEC form 8
2023-05-10 00:00 ET
Myomo reported for 2023 q1
SEC form 10
2023-05-10 00:00 ET
Myomo reported for 2023 q1
SEC form 6
2023-04-10 08:46 ET
Myomo published news for 2023 q1
SEC form 10
2023-03-13 15:49 ET
Myomo reported for 2022 q4
SEC form 6
2023-03-13 08:40 ET
Myomo reported for 2022 q4
SEC form 8
2023-03-13 00:00 ET
Myomo reported for 2022 q4
SEC form 10
2023-03-13 00:00 ET
Myomo reported for 2022 q4
SEC form 6
2023-01-30 16:16 ET
Myomo published news for 2022 q4
SEC form 6
2023-01-13 17:17 ET
Myomo published news for 2022 q4
SEC form 6
2023-01-10 16:35 ET
Myomo published news for 2022 q4
SEC form 6
2022-12-07 16:16 ET
Myomo published news for 2022 q3
SEC form 10
2022-11-10 16:28 ET
Myomo reported for 2022 q3
SEC form 6
2022-11-10 16:22 ET
Myomo reported for 2022 q3
SEC form 8
2022-11-10 00:00 ET
Myomo reported for 2022 q3
SEC form 10
2022-11-10 00:00 ET
Myomo reported for 2022 q3
SEC form 6
2022-10-28 08:31 ET
Myomo published news for 2022 q3
SEC form 6
2022-10-18 17:01 ET
Myomo published news for 2022 q3
SEC form 6
2022-09-27 17:00 ET
Myomo published news for 2022 q2
SEC form 10
2022-08-03 16:17 ET
Myomo reported for 2022 q2
SEC form 6
2022-08-03 16:10 ET
Myomo published news for 2022 q2
SEC form 8
2022-08-03 00:00 ET
Myomo reported for 2022 q2
SEC form 10
2022-08-03 00:00 ET
Myomo reported for 2022 q2
SEC form 6
2022-08-02 17:19 ET
Myomo published news for 2022 q2
SEC form 6
2022-07-07 16:15 ET
Myomo published news for 2022 q2
SEC form 6
2022-06-10 16:06 ET
Myomo published news for 2022 q1
SEC form 10
2022-05-11 16:16 ET
Myomo reported for 2022 q1
SEC form 6
2022-05-11 16:10 ET
Myomo published news for 2022 q1
SEC form 8
2022-05-11 00:00 ET
Myomo reported for 2022 q1
SEC form 10
2022-05-11 00:00 ET
Myomo reported for 2022 q1
SEC form 6
2022-04-29 08:30 ET
Myomo published news for 2022 q1
SEC form 6
2022-04-04 16:31 ET
Myomo published news for 2022 q1
SEC form 10
2022-03-11 14:51 ET
Myomo published news for 2021 q4
SEC form 10
2022-03-11 00:00 ET
Myomo published news for 2021 q4
SEC form 6
2022-03-09 16:11 ET
Myomo published news for 2021 q4
SEC form 8
2022-03-09 00:00 ET
Myomo published news for 2021 q4
SEC form 6
2022-01-10 08:35 ET
Myomo published news for 2021 q4
SEC form 6
2022-01-05 16:16 ET
Myomo published news for 2021 q4
SEC form 6
2021-12-16 16:15 ET
Myomo published news for 2021 q3
SEC form 10
2021-11-10 16:48 ET
Myomo published news for 2021 q3
SEC form 6
2021-11-10 16:11 ET
Myomo published news for 2021 q3
SEC form 10
2021-11-10 00:00 ET
Myomo published news for 2021 q3
SEC form 8
2021-11-10 00:00 ET
Myomo published news for 2021 q3
SEC form 6
2021-10-15 09:25 ET
Myomo published news for 2021 q3
SEC form 6
2021-10-05 16:31 ET
Myomo published news for 2021 q3
SEC form 10
2021-08-09 16:17 ET
Myomo published news for 2021 q2
SEC form 6
2021-08-09 16:10 ET
Myomo published news for 2021 q2
SEC form 10
2021-08-09 00:00 ET
Myomo published news for 2021 q2
SEC form 6
2021-06-29 16:06 ET
Myomo published news for 2021 q1
SEC form 6
2021-06-25 16:17 ET
Myomo published news for 2021 q1
SEC form 6
2021-06-15 16:30 ET
Myomo published news for 2021 q1
SEC form 6
2021-06-08 08:30 ET
Myomo published news for 2021 q1
SEC form 10
2021-05-05 16:15 ET
Myomo published news for 2021 q1
SEC form 6
2021-05-05 16:10 ET
Myomo published news for 2021 q1
SEC form 10
2021-05-05 00:00 ET
Myomo published news for 2021 q1
SEC form 6
2021-04-28 17:01 ET
Myomo published news for 2021 q1
SEC form 6
2021-04-28 16:15 ET
Myomo published news for 2021 q1
SEC form 6
2021-04-16 17:01 ET
Myomo published news for 2021 q1
SEC form 6
2021-04-06 17:00 ET
Myomo published news for 2021 q1
SEC form 10
2021-03-10 16:21 ET
Myomo published news for 2020 q4
SEC form 6
2021-03-10 16:10 ET
Myomo published news for 2020 q4
SEC form 6
2021-01-26 06:46 ET
Myomo published news for 2020 q4
SEC form 6
2021-01-19 17:22 ET
Myomo published news for 2020 q4
SEC form 6
2021-01-11 06:41 ET
Myomo published news for 2020 q4
SEC form 6
2020-12-16 16:15 ET
Myomo published news for 2020 q3
SEC form 10
2020-11-10 16:17 ET
Myomo published news for 2020 q3
SEC form 6
2020-11-10 16:10 ET
Myomo published news for 2020 q3